Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GABRA3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GABRA3 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View GABRA3 Products |
| Gene Delivery | GABRA3 Full-Length ORF Lentivirus / Promise-ORF. For stable cell lines preserving native ion channel conformation. Essential for electrophysiology. | View GABRA3 Products |
| Benchmark Ab | Anti-GABRA3 Recombinant Antibody. Sequence-defined positive control for binding assay validation. Endotoxin controlled. | View GABRA3 Products |
| Validator | GABRA3 siRNA Set. For knockdown verification and specificity confirmation in cell-based assays. | View GABRA3 Products |
| Related Target A | GABRA1 (GABA-A Receptor Alpha 1). Counter-screening for sedation liability assessment (α1-sparing selectivity). | View GABRA1 Products |
| Related Target B | GABRA5 (GABA-A Receptor Alpha 5). Cognition-related selectivity panel member. | View GABRA5 Products |
| Related Target C | GABRB3 (GABA-A Receptor Beta 3). Crucial beta subunit for functional pentameric receptor assembly. | View GABRB3 Products |
| Related Target D | GABRG2 (GABA-A Receptor Gamma 2). Required subunit for functional pentameric receptor assembly and benzodiazepine binding site formation. | View GABRG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subunit Selectivity (α3 vs α1/α5) | Human/Mouse/Rat ortholog panels for GABRA3, GABRA1, GABRA5 available with >95% purity and sequence verification by Mass Spec. |
| Native Ion Channel Conformation | Lentivirus Premade Particles for stable cell line generation; preserves transmembrane topology essential for electrophysiology and chloride flux assays. |
| Heteropentameric Assembly | Co-expression support with GABRB and GABRG subunits; cell lines available for complex formation studies. |
| Specificity Validation | Endotoxin-controlled (<1 EU/µg) proteins and validated siRNA for definitive target engagement confirmation. |
| Subfamily Counter Screening (GABRA1/2/4/5/6) | Homolog panel lentivirus vectors strictly sequence verified for high-fidelity selectivity assays. |
| Lack of Reliable Controls | Recombinant benchmark antibodies available as assay standards. |
| False Positives in Endogenous Assays | Validated siRNA included for precise specificity and background checks. |
Live GABRA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GABRA3-selective therapeutics is intensifying. Major players are shifting focus from broad-spectrum GABA-A modulators (e.g., non-selective benzodiazepines) to subunit-selective approaches that minimize sedation liability. First-generation α3-preferring modulators are reaching preclinical and early clinical stages. The next wave targets oncology applications (breast cancer stem cells, solid tumors) and rare genetic disorders (Angelman Syndrome, epileptic encephalopathies). Emerging modalities include monoclonal antibodies, gene therapy, and targeted biologics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Subunit-Selective Small Molecules (PAMs) | Ovid Therapeutics, Cerevel, Saniona, Academic Consortia | Angelman Syndrome, Epilepsy, Anxiety | Selectivity Assay (need ortholog protein panels, lentivirus cell lines for patch-clamp) |
| Allosteric Modulators | Marinus Pharmaceuticals (peripheral) | Anxiety Disorders | Binding Site Mapping (need high-purity ECD proteins) |
| Monoclonal Antibody / ADC | Academic / Emerging Biotech | Solid Tumors (Breast, Lung) | Binding / Internalization (need high-purity ECD and cell lines) |
| Gene Therapy | Various | Rare Epileptic Encephalopathies | Rescue Validation (need specific siRNA and benchmark Abs) |